文献速递免疫规划妇幼与学校卫生

多组分P3-MumBubVax产前干预促进母婴疫苗接种的可行性与可接受性:一项先导研究

Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: A pilot study.
PubMed 文献 · Vaccine · 2020-04-19

在澳大利亚墨尔本皇家妇女医院招募25名助产士和62名孕18-22周孕妇,评估多组分P3-MumBubVax干预的可行性与可接受性。干预后调查显示助产士和孕妇满意度高,自报流感疫苗接种率82%、百日咳疫苗接种率93%,婴儿12周完全接种率96%。结论认为该干预在澳大利亚公立产前环境中可行且可接受,需进一步评估有效性。

要点

  • 该干预在澳大利亚公立产前环境中可行且可接受。
  • 干预后自报孕妇流感疫苗接种率82%,百日咳疫苗接种率93%。
  • 96%的婴儿在12周时完成完全接种。

核心结论

  • P3-MumBubVax干预在澳大利亚公立产前环境中可行且可接受,需进一步评估以确定有效性。

研究设计与样本

  • 在澳大利亚墨尔本皇家妇女医院招募25名助产士和62名孕18-22周孕妇的先导研究,干预后通过在线调查评估可行性、实施、可接受性和对疫苗接种率的影响。

主要发现

  • 25名助产士中19名完成培训,18名助产士和56名孕妇返回问卷。
  • 14/18名助产士报告使用贴纸提示,10/18名报告使用或参考网站,11/18名报告使用情况说明单。
  • 48/56名孕妇(86%)报告与助产士讨论了流感疫苗,46/56名(82%)讨论了百日咳疫苗;48/56名(87%)报告对话时长为1-3分钟。
  • 所有助产士对干预满意,17/18名报告干预后讨论疫苗的信心增强;孕妇对短信内容(50/56;94%)、发送时机(49/55;89%)和疫苗讨论总体(34/56;63%)非常满意,但16/54名(30%)希望更多讨论儿童疫苗。
  • 自报孕妇流感疫苗接种率为82%(45/55),百日咳疫苗接种率为93%(51/55),基线2017-2018年为流感43%、百日咳60%;96%(50/52)的婴儿在12周时完全接种。

关键数值与推荐

  • 干预包括三个层面:实践层面(疫苗倡导者、提示和记录疫苗接种讨论/实施的贴纸);提供者层面(含疫苗沟通培训的网站、学习练习、情况说明单、儿童疫苗接种资源链接);家长层面(短信提醒、网站、情况说明单)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步评估以确定有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancy is a critical time for vaccine decision-making, but coverage remains suboptimal for maternal influenza (45-60%) and pertussis vaccination (65-80%) in Australia. The multi-component P3-MumBubVax intervention has been designed for Australian midwives to optimise antenatal vaccine discussions and improve maternal and childhood vaccine uptake. A pilot study was conducted to assess intervention feasibility and acceptability. METHODS: P3-MumBubVax includes components at three levels: 1. Practice ('vaccine champions'; stickers to prompt and record vaccine discussions/delivery); 2. Provider (website with vaccine communication training; learning exercise; fact sheets; links to child vaccination resources); 3. Parent (SMS reminders; website; fact sheets). Midwives and pregnant women 18-22 weeks gestation were recruited at the Royal Women's Hospital, Melbourne. Post-intervention online surveys assessed intervention feasibility, implementation, acceptability and impact on vaccine uptake. RESULTS: Twenty-five midwives and 62 pregnant women were recruited and 19/25 midwives completed training. Surveys were returned by 18/25 midwives and 56/62 women. 14/18 midwives reported using the sticker prompts, 10/18 reported using or referring to the website, and 11/18 reported using the fact sheets. 48/56 pregnant women (86%) reported discussing influenza and 46/56 (82%) discussed pertussis vaccines with their midwives. These conversations were reported to be short (1-3 min) for 48/56 women (87%). All midwives were satisfied with the intervention and 17/18 reported feeling more confident discussing vaccines following the intervention. Women were very satisfied with SMS content (50/56; 94%) and timing (49/55; 89%), and with their vaccine discussions in general (34/56; 63%). However, 16/54 (30%) wanted more discussion about childhood vaccines. Self-reported maternal vaccine uptake was 82% (45/55) and 93% (51/55) for influenza and pertussis (baseline 2017-2018: 43% influenza, 60% pertussis) and 96% (50/52) of infants were fully vaccinated at 12 weeks. DISCUSSION: The P3-MumBubVax intervention is feasible and acceptable in the Australian public antenatal setting. Further evaluation is required to determine effectiveness.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kaufman J, Attwell K, Tuckerman J, et al. Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: A pilot study. Vaccine. 2020. PMID: 32321684. doi:10.1016/j.vaccine.2020.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。